179 related articles for article (PubMed ID: 11919245)
21. Gemcitabine plus paclitaxel as first-line chemotherapy for patients with advanced breast cancer.
Delfino C; Caccia G; Gonzáles LR; Mickiewicz E; Rodger J; Balbiani L; Morales DF; Comba AZ; Brosio C
Oncology; 2004; 66(1):18-23. PubMed ID: 15031594
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of gemcitabine/irinotecan in refractory or relapsed small-cell lung cancer.
Schuette W; Nagel S; Juergens S; Bork I; Wollschlaeger B; Schaedlich S; Blankenburg T
Clin Lung Cancer; 2005 Sep; 7(2):133-7. PubMed ID: 16179101
[TBL] [Abstract][Full Text] [Related]
23. Effects of sequential paclitaxel-carboplatin followed by gemcitabine-based chemotherapy compared with paclitaxel-carboplatin therapy administered to patients with advanced epithelial ovarian cancer: A retrospective, STROBE-compliant study.
Wang F; Du X; Li X; Liu N; Yu H; Sheng X
Medicine (Baltimore); 2016 Dec; 95(51):e5696. PubMed ID: 28002342
[TBL] [Abstract][Full Text] [Related]
24. Paclitaxel in salvage therapy for germ cell tumors.
Motzer RJ
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-83-S15-85. PubMed ID: 9346229
[TBL] [Abstract][Full Text] [Related]
25. Treatment of patients with cisplatin-refractory testicular germ-cell cancer. German Testicular Cancer Study Group (GTCSG).
Bokemeyer C; Kollmannsberger C; Harstrick A; Beyer J; Gerl A; Casper J; Metzner B; Hartmann JT; Schmoll HJ; Kanz L
Int J Cancer; 1999 Dec; 83(6):848-51. PubMed ID: 10597209
[TBL] [Abstract][Full Text] [Related]
26. Long-term survival with paclitaxel and gemcitabine for germ cell tumors after progression following high-dose chemotherapy with tandem transplant.
Mulherin BP; Brames MJ; Einhorn LH
Am J Clin Oncol; 2015 Aug; 38(4):373-6. PubMed ID: 26214082
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of gemcitabine in refractory germ cell tumors.
Einhorn LH; Stender MJ; Williams SD
J Clin Oncol; 1999 Feb; 17(2):509-11. PubMed ID: 10080592
[TBL] [Abstract][Full Text] [Related]
28. Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: pathologic complete response and longitudinal assessment of impact on cognitive functioning.
Hensley ML; Correa DD; Thaler H; Wilton A; Venkatraman E; Sabbatini P; Chi DS; Dupont J; Spriggs D; Aghajanian C
Gynecol Oncol; 2006 Aug; 102(2):270-7. PubMed ID: 16490239
[TBL] [Abstract][Full Text] [Related]
29. Gemcitabine and paclitaxel in metastatic breast cancer: a review.
Colomer R
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 12):8-12. PubMed ID: 15685819
[TBL] [Abstract][Full Text] [Related]
30. Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
Sledge GW
Oncology (Williston Park); 2003 Dec; 17(12 Suppl 14):33-5. PubMed ID: 14768403
[TBL] [Abstract][Full Text] [Related]
31. A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Ryan DP; Lynch TJ; Grossbard ML; Seiden MV; Fuchs CS; Grenon N; Baccala P; Berg D; Finkelstein D; Mayer RJ; Clark JW
Cancer; 2000 Jan; 88(1):180-5. PubMed ID: 10618622
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of gemcitabine and paclitaxel in advanced solid tumors.
Lim N; Lara PN; Lau DH; Edelman MJ; Tanaka M; al-Jazayrly G; Houston J; Lauder I; Gandara DR
Cancer Invest; 2003; 21(1):7-13. PubMed ID: 12643004
[TBL] [Abstract][Full Text] [Related]
33. Future directions in the chemotherapy of ovarian cancer.
Ozols RF
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
[TBL] [Abstract][Full Text] [Related]
34. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (Stage IIIB/IV) non-small cell lung cancer.
Chen YM; Perng RP; Yang KY; Liu TW; Tsai CM; Ming-Liu J; Whang-Peng J
Chest; 2000 Jun; 117(6):1583-9. PubMed ID: 10858387
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of a cremophor-free, polymeric micelle formulation of paclitaxel for patients with advanced urothelial cancer previously treated with gemcitabine and platinum.
Lee JL; Ahn JH; Park SH; Lim HY; Kwon JH; Ahn S; Song C; Hong JH; Kim CS; Ahn H
Invest New Drugs; 2012 Oct; 30(5):1984-90. PubMed ID: 22012004
[TBL] [Abstract][Full Text] [Related]
36. Sequential therapy in advanced non-small-cell lung cancer with weekly paclitaxel followed by cisplatin-gemcitabine-vinorelbine. A phase II study.
Feliu J; Martin G; Lizón J; Chacón JI; Dorta J; de Castro J; Rodríguez A; Sánchez Heras B; Torrego JC; Espinosa E; González Barón M;
Ann Oncol; 2001 Oct; 12(10):1369-74. PubMed ID: 11762806
[TBL] [Abstract][Full Text] [Related]
37. Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.
Paccagnella A; Oniga F; Bearz A; Favaretto A; Clerici M; Barbieri F; Riccardi A; Chella A; Tirelli U; Ceresoli G; Tumolo S; Ridolfi R; Biason R; Nicoletto MO; Belloni P; Veglia F; Ghi MG
J Clin Oncol; 2006 Feb; 24(4):681-7. PubMed ID: 16446341
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel and gemcitabine combination in a biweekly schedule in patients with advanced non small-cell lung cancer: a phase I study.
Athanasiadis A; Roussos G; Papakostoulis T; Athanasiadou DC; Stathopoulos GP
Cancer Chemother Pharmacol; 2005 Dec; 56(6):653-8. PubMed ID: 15937714
[TBL] [Abstract][Full Text] [Related]
39. Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours.
Nicolai N; Necchi A; Gianni L; Piva L; Biasoni D; Torelli T; Stagni S; Milani A; Pizzocaro G; Salvioni R
BJU Int; 2009 Aug; 104(3):340-6. PubMed ID: 19239440
[TBL] [Abstract][Full Text] [Related]
40. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
